News
Avacta Group PLC - Directorate Change
RNS Number: 3020 J Avacta Group PLC 29 March 2018. Avacta Group plc, the developer of Affimer ® biotherapeutics and research reagents, announces that Dr Michael Albin, one of the Group's Non-Executive Directors will be stepping down from the Board with effect from 30 March 2018.. Antibodies dominate markets worth in excess of $100 bn despite their shortcomings.
RNS Number: 3020 J Avacta Group PLC 29 March 2018. Avacta Group plc, the developer of Affimer ® biotherapeutics and research reagents, announces that Dr Michael Albin, one of the Group's Non-Executive Directors will be stepping down from the Board with effect from 30 March 2018.. Antibodies dominate markets worth in excess of $100 bn despite their shortcomings.